Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
Bristol-Myers Squibb
QuantumLeap Healthcare Collaborative
University of Ulm
University of California, San Diego
University of California, San Diego
Centre Leon Berard
Gustave Roussy, Cancer Campus, Grand Paris
University of Kentucky
University of California, San Diego
BioAtla, Inc.
The University of Texas Health Science Center, Houston
Sheba Medical Center
Mural Oncology, Inc
Merck Sharp & Dohme LLC
Duke University
Mural Oncology, Inc
University Health Network, Toronto
The Netherlands Cancer Institute
Sunnybrook Health Sciences Centre
Tesaro, Inc.
Melanoma Institute Australia
Canadian Myeloma Research Group
Fudan University
Sheba Medical Center
Vall d'Hebron Institute of Oncology
DNAtrix, Inc.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Oncovir, Inc.
NYU Langone Health
GlaxoSmithKline
Pancreatic Cancer Research Team